ETS transcription factor ERG cooperates with histone demethylase KDM4A

TAE-DONG KIM¹, SOOK SHIN¹,² and RALF JANKNECHT¹,²

¹Department of Cell Biology, University of Oklahoma Health Sciences Center; ²Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Received December 7, 2015; Accepted January 11, 2016

DOI: 10.3892/or.2016.4747

Abstract. ERG (ETS-related gene) is a member of the ETS (erythroblast transformation-specific) family of transcription factors. Overexpression of the ERG transcription factor is observed in half of all prostate tumors and is an underlying cause of this disease. However, the mechanisms involved in the functions of ERG are still not fully understood. In the present study, we showed that ERG can directly bind to KDM4A (also known as JMJD2A), a histone demethylase that particularly demethylates lysine 9 on histone H3. ERG and KDM4A cooperated in upregulating the promoter of Yes-associated protein 1 (YAP1), a downstream effector in the Hippo signaling pathway and crucial growth regulator. Multiple ERG binding sites within the human YAP1 gene promoter were identified and their impact on transcription was determined through mutational analysis. Furthermore, we found that ERG expression reduced histone H3 lysine 9 trimethylation at the YAP1 gene promoter, consistent with its epigenetic regulation through the ERG interaction partner, KDM4A. Finally, downregulation of YAP1 phenocopied the growth-retarding effect of ERG or KDM4A depletion in human VCaP prostate cancer cells. Collectively, these results elucidated a novel mechanism - ERG promotes prostate tumorigenesis together with KDM4A through the upregulation of YAP1. A corollary is that KDM4A as well as YAP1 inhibitors may prove beneficial for the therapy of ERG-overexpressing prostate tumors.

Introduction

Prostate cancer is among the most common neoplasias in men and a leading cause of death (1). Although the majority of prostate tumor patients are diagnosed with localized disease that can be efficiently treated with surgery and radiation therapy, men presenting with metastasized prostate tumors have a much bleaker survival chance. Thus, there is a critical need to develop new avenues of therapy, which may arise from a better understanding of the molecular changes in prostate cancer cells (2).

In approximately half of all human prostate tumors, the gene encoding the ETS transcription factor, ERG, becomes translocated, resulting in the overexpression of the ERG protein (3,4). Mimicking this overexpression in the prostates of mice led to the development of the precursor of prostate carcinomas, prostate intraepithelial neoplasia (5,6). One research group even reported that very high prostate-specific expression of ERG induced carcinoma formation in approximately half of the respective transgenic mice at old age (7). Furthermore, when combined with knockout of the tumor-suppressor phosphatase and tensin homolog (PTEN), ERG overexpression accelerated prostate cancer development (8-11). These data implicate a causal role for ERG in the development of prostate tumors. However, the molecular details of how ERG overexpression contributes to the neoplastic transformation of prostate cells are far from resolved.

In the present study, we identified lysine demethylase 4A (KDM4A), also known as Jumonji C domain-containing protein 2A (JMJD2A), as a novel interaction partner of ERG. Furthermore, we found that ERG and KDM4A cooperated in regulating the transcription of the Yes-associated protein 1 (YAP1) gene, which is a downstream effector in the Hippo signaling pathway that plays important roles in development, homeostasis and cancer (12,13).

Materials and methods

Luciferase assays. Human VCaP prostate cancer cells were grown in 6-wells at 37°C in a humidified atmosphere containing 5% CO₂ and were transfected utilizing 8 μg polyethylenimine. In general, 1,500 ng pBluescript KS⁺ as a carrier and 500 ng of indicated luciferase reporter gene constructs, which were based on the pGL2-Basic plasmid (Promega) and contained human YAP1 promoter fragments (amplified out of LNCaP prostate cancer cells) cloned between the Smal and HindIII sites, were used for transfection. In addition, indicated amounts of ERG expression plasmid, empty vector pEV3S and Flag-tagged KDM4A (or its H188A mutant) expression vector were co-transfected. Cells were lysed 36 h after transfection and
luciferase activity was measured as previously reported (14). In the case of human BPH-1 normal prostate cells, they were grown in 12-wells and transfected with 500 ng pBluescript KS+ and 500 ng YAPI (-390/+22) luciferase reporter construct utilizing 2 µg polyethyleneimine. Similarly, human LAP-C4 prostate cancer cells were grown in 12-wells and transfected with 750 ng pBluescript KS+ and 250 ng YAPI (-390/+22) luciferase reporter plasmid also using 2 µg polyethyleneimine, whereas 200 ng luciferase reporter construct, 800 ng pBluescript KS+, 1 ng ERG expression plasmid or pEV3S, and 2.5 µg polyethyleneimine were employed in the case of human embryonic kidney 293T cells.

Preparation of protein extracts. Human 293T cells were seeded onto poly-L-lysine-coated 6-cm dishes (15) and transiently transfected by the calcium phosphate coprecipitation method (16) with 4.5 µg pBluescript KS+ and either 4.5 µg empty vector pEV3S or ERG-Myc-Flag expression plasmid. Thirty-six hours after transfection, cells were washed once with phosphate-buffered saline and cells were detached by a 5-min incubation in 40 mM HEPES (pH 7.4), 150 mM NaCl, 10 mM EDTA, after which cells were sprayed off by pipetting. Then, cells were collected by centrifugation and resuspended in 150 µl of 10 mM Tris, 30 mM Na4P2O7 (pH 7.1), 175 mM NaCl, 50 mM NaF, 2 mM dithiothreitol, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 2 µg/ml aprotinin, 1 µg/ml pepstatin, lysed for 30 min on ice and debris was removed by centrifugation (17). Extracts were radioactively labeled with 32P-dATP by filling in 5'-overhanging ends with Klenow DNA polymerase (20). Binding of proteins to the radiolabeled probes was measured by electrophoretic mobility shift assay. Wild-type or mutated E74 oligonucleotides, which were previously described (19), were 5'-radiolabeled (21) and hybridized to obtain double-stranded oligonucleotides. Then, they were radioactively labeled with ³²P-dATP by filling in 5'-overhanging ends with Klenow DNA polymerase (20). Binding of 0.1 µl protein extract to ~0.25 ng ³²P-labeled oligonucleotide occurred in 10 µl of 20 mM HEPES (pH 7.4), 25 mM NaCl, 0.5 mM EDTA, 0.1 µg/ml bovine serum albumin, 0.05 µg/µl poly(dI-dC)-poly(dI-dC), 2 mM dithiothreitol, 0.01% Tween-20 and 12% glycerol (21). As indicated, 0.05 µl of anti-Myc (9E10 mouse monoclonal antibody; M4439; Sigma) or anti-HA (12CA5 mouse monoclonal antibody; ab16918; Abcam) antibody was added. For competition experiments, 0.05 µl unlabeled oligonucleotide (12.5 ng) was additionally added. After a 30-min incubation on ice, the binding reactions were electrophoresed at 4°C on 4% native acrylamide gels as previously described (19) to reveal either Coomassie staining or anti-Flag (M2 mouse monoclonal antibody; 9E10; Sigma) western blotting (25).

Electrophoretic mobility shift assay. Human embryonic kidney 293T cells, which were grown in 6-cm dishes, were transfected using the calcium phosphate coprecipitation method (26) with expression plasmids encoding Myc-tagged ERG and HA-tagged KDM4A. Thirty-six hours after transfection, cells were lysed and immunoprecipitations with anti-Myc mouse monoclonal antibodies (9E10; M4439; Sigma) or anti-HA (12CA5 mouse monoclonal antibody; ab16918; Abcam) antibody was added. For competition experiments, 0.05 µl unlabeled oligonucleotide (12.5 ng) was additionally added. After a 30-min incubation on ice, the binding reactions were electrophoresed at 4°C on 4% native acrylamide gels as previously described (19) to reveal either Coomassie staining or anti-Flag (M2 mouse monoclonal antibody; F3165; Sigma) western blotting (25).
formaldehyde for 12 min at room temperature (30). Lysis of cells, sonication of resultant extracts and chromatin immunoprecipitations were then performed as previously described (31). The following rabbit polyclonal antibodies were employed: H3K4me3 (2.4 µg; ab8580; Abcam), H3K9me3 (3 µg; 07-442), H3K27me3 (4 µg; 07-449) (both from Upstate) and H3K36me3 (2 µg; ab9050; Abcam). Immunoprecipitated DNA fragments were amplified by PCR using the GoTaq DNA polymerase kit (M3008; Promega, Fitchburg, WI, USA) according to the manufacturer's recommendation and with the following temperature program (32): 2 min at 98˚C; 8 cycles at 98˚C for 25 sec, 65˚C (-1˚C/cycle) for 25 sec, 72˚C for 25 sec; 25 cycles (or 20 cycles for input DNA) at 98˚C for 25 sec, 57˚C for 25 sec, 72˚C for 25 sec (+1 sec/cycle); 72˚C for 4 min as a final additional extension step. Primers used were: YAP1-2561-f (5'-GGCGAACTGGAAGCGCCTTTCC-3') and YAP1-2989-r (5'-GAGACAGAAACTCGCCTAAACGC-3'), yielding a 429-bp PCR product. Please note that these two primers can potentially amplify both the endogenous YAP1 promoter as well as the YAP1 promoter fragment in the YAP1 (-496/+22) luciferase reporter; however the utilized PCR cycle number was too low to detect any endogenous YAP1 promoter signals. In case of input DNA, the alternative primers: pGL2, sense (5’-CACTGCATTCTAGTTGTGGTTTGTCC-3’) and YAP1-2845-r (5’-CGCTGCAAGTTGCTACATTCCTGC-3’) were utilized that yielded a 419-bp PCR product. All PCR products were separated on 1.5% agarose gels and visualized with ethidium bromide staining (33).

Knockdown experiments. Oligonucleotides encoding shRNAs were inserted into the pSIREN-RetroQ (Clontech, Mountain View, CA, USA) retroviral vector and targeted the following human sequences: ERG #1 (5’-GGCGAACTGGAAGCGCCTTTCC-3’) and YAP1-2989-r (5’-GAGACAGAAACTCGCCTAAACGC-3’), yielding a 429-bp PCR product. Please note that these two primers can potentially amplify both the endogenous YAP1 promoter as well as the YAP1 promoter fragment in the YAP1 (-496/+22) luciferase reporter; however the utilized PCR cycle number was too low to detect any endogenous YAP1 promoter signals. In case of input DNA, the alternative primers: pGL2, sense (5’-CACTGCATTCTAGTTGTGGTTTGTCC-3’) and YAP1-2845-r (5’-CGCTGCAAGTTGCTACATTCCTGC-3’) were utilized that yielded a 419-bp PCR product. All PCR products were separated on 1.5% agarose gels and visualized with ethidium bromide staining (33).

Statistical analysis. Averages with standard deviations of at least three experiments were calculated, and statistical significance was assessed by performing an unpaired, two-tailed t-test. P≤0.05 was considered to indicate statistical significance.

Results

Activation of the human YAP1 promoter by ERG. Previously, it was shown that the ETS transcription factor GABP can bind to and stimulate the promoter of the mouse YAP1 gene, whereas ERG seemingly was incapable of doing so (36). In contrast, a recent report indicated that ERG promotes transcription of the human YAP1 gene (7). To clarify this discrepancy, we employed a luciferase reporter gene controlled by the human YAP1 promoter as well as the YAP1 promoter fragment in the YAP1 (-496/+22) luciferase reporter; however the utilized PCR cycle number was too low to detect any endogenous YAP1 promoter signals. In case of input DNA, the alternative primers: pGL2, sense (5’-CACTGCATTCTAGTTGTGGTTTGTCC-3’) and YAP1-2845-r (5’-CGCTGCAAGTTGCTACATTCCTGC-3’) were utilized that yielded a 419-bp PCR product. All PCR products were separated on 1.5% agarose gels and visualized with ethidium bromide staining (33).

Figure 1. Activation of the human YAP1 gene promoter by ERG. Increasing amounts of ERG expression vector were transfected into cancerous VCaP and LAP-C4 or benign BPH-1 prostate cells and the activity of a cotransfected YAP1 (-390/+22) luciferase reporter construct was determined. Shown increases in luciferase activities (averages with standard deviations) upon ERG expression were normalized to the respective amount of transfected empty vector.

Knockdown experiments. Oligonucleotides encoding shRNAs were inserted into the pSIREN-RetroQ (Clontech, Mountain View, CA, USA) retroviral vector and targeted the following human sequences: ERG #1 (5’-GGCGAACTGGAAGCGCCTTTCC-3’), ERG #3 (5’-GGCGAACTGGAAGCGCCTTTCC-3’), KDM4A #3 (5’-GTGGAAGATGTGCAAGA-3’), KDM4A #4 (5’-GTGGAAGATGTGCAAGA-3’), YAP1 #2 (5’-GCTTAAGGGCAATGAGA-3’), YAP1 #3 (5’-AGT AAAGTGGTGGTGA-3’). Retrovirus was generated as previously described (34) and used to transfect VCaP cells followed by selection with 1 µg/ml puromycin (35). Cell growth was then measured with the PrestoBlue cell viability kit (Invitrogen) according to the recommendations of the manufacturer. For this, cells were seeded into 96-well plates, grown for 1-5 days, treated with PrestoBlue reagent for 1 h, excited with 530 nm light and fluorescence was measured at 590 nm.

Activation of the human YAP1 promoter by ERG. Previously, it was shown that the ETS transcription factor GABP can bind to and stimulate the promoter of the mouse YAP1 gene, whereas ERG seemingly was incapable of doing so (36). In contrast, a recent report indicated that ERG promotes transcription of the human YAP1 gene (7). To clarify this discrepancy, we employed a luciferase reporter gene controlled by the human YAP1 promoter and transfected it into three different human cell lines: VCaP, a prostate cancer cell line characterized by the TMPRSS2-ERG translocation (3), another prostate cancer cell line (LAP-C4) that is devoid of such a translocation (37), and benign BPH-1 prostate cells. In all three cell lines, we observed a dose-dependent activation of the YAP1 gene promoter by ERG (Fig. 1). In VCaP and BPH-1 cells, 5 ng ERG expression vector was sufficient to elicit a maximal response, and 25 ng expression vector led to a slight reduction of promoter activity. In contrast, LAP-C4 cells displayed the highest YAP1 promoter activity at 1 ng ERG expression vector, and larger amounts led progressively to greatly reduced luciferase activities. Such a behavior is likely due to squelching, the titration of limiting cofactors by an abundance of ERG. Regardless, our data showed that ERG is capable of stimulating the human YAP1 gene promoter in various prostate cell lines.

Direct binding of ERG to ETS sites within the human YAP1 promoter. Although ERG was found to interact with the human YAP1 promoter in chromatin immunoprecipitation
assays (7), it has remained unresolved whether this is due to direct DNA-binding of ERG. Analysis of the human YAP1 promoter revealed the presence of eight potential ETS binding sites (Fig. 2A) that are characterized by a 5'-GGAA/T-3' core sequence (38) and may be bound by ERG. Thus, we expressed Myc-tagged ERG in human 293T cells that have no detectable endogenous ERG (Fig. 2B), and prepared cell extracts to probe for a potential binding of ERG to the ETS sites in the YAP1 gene promoter. To this end, we generated 32P-labeled oligonucleotides encompassing these ETS sites and incubated them with control lysate or lysate from ERG-transfected 293T cells. In preliminary experiments (data not shown, but see also Fig. 2D), we observed that ERG alone did not bind to any of the ETS sites within the YAP1 promoter. However, it is known that ERG DNA-binding is auto-inhibited and this inhibition may be relieved by interaction with other proteins (39). Since our ERG expression construct contained a C-terminal Myc-tag, we employed anti-Myc antibodies to emulate such a protein-protein interaction and indeed, this resulted into noticeable DNA-binding (Fig. 2C); please note that we cannot exclude other explanations why the anti-Myc antibodies promoted DNA-binding of ERG, such as the disruption of binding of an ERG inhibitor that is present in lysates from 293T cells. In particular, we observed binding to oligonucleotides encompassing the juxtaposed ETS sites 1 and 2 as well as ETS sites 6 and 7. Binding to ETS sites 6 and 7 appeared to be stronger than to ETS sites 1 and 2 (Fig. 2C; and more visible in the shorter exposures of autoradiograms shown in Fig. 2D).

Figure 2. *In vitro* binding of ERG to the YAP1 promoter. (A) Sequence of the eight putative ETS binding sites within the human YAP1 gene promoter from -390 to +22. Also shown is the consensus DNA-binding sequence for ERG. (B) Western blotting shows the degree of ERG expression in the transfected 293T cells. Actin levels serve as a control. (C) *In vitro* binding of ERG to 32P-labeled oligonucleotides encompassing the indicated ETS sites or the E74 oligonucleotide. Mutation of ETS site 1, 2, 6 or 7 is marked by the prefix 'm'. Asterisks denote ERG, DNA complexes. (D) DNA-binding assays with indicated radioactively labeled oligonucleotides. Inclusion of antibodies (anti-Myc or anti-HA) and unlabeled competitor oligonucleotides (E74 or the mutated mE74) is indicated.
No binding to ETS sites 3, 4, 5 and 8 was detected (Fig. 2C), consistent with those four ETS sites being very divergent to the ERG consensus site of 5'-ACCGGAAGT-3' (40). In addition, as a positive control, we observed DNA-binding to the E74 site, a paradigmatic ETS binding site that was shown to interact with various ETS proteins (19,41,42).

To determine whether ERG binds to both ETS sites 1 and 2, we mutated each one individually in the '1/2' oligonucleotide. Mutation of either ETS site 1 or 2 resulted in similarly reduced ERG binding (Fig. 2C), indicating that ERG can interact with ETS sites 1 and 2 with comparable affinity. Likewise, we observed that mutation of either ETS site 6 or 7 reduced ERG binding to the 32P-labeled '6/7' oligonucleotide (Fig. 2C). However, whereas mutation of ETS site 7 somewhat reduced DNA-binding, mutation of ETS site 6 completely abolished DNA-binding, suggesting that ERG binding to ETS site 7 is dependent on the integrity of ETS site 6. Lastly, we assessed the specificity of the observed DNA-binding. An excess of this oligonucleotide suppressed binding to the 32P-labeled '1/2' and '6/7' oligonucleotides (Fig. 2D). In contrast, a mutated E74 oligonucleotide that no longer binds to ETS proteins was unable to compete for binding. In conclusion, our data show that ERG can directly bind to several ETS sites within the human YAP1 gene promoter.

Importance of ETS sites 6 and 7. Next, we started to evaluate which of the ERG binding sites in the YAP1 promoter are crucial for its activity. First, we employed promoter truncations. The -180/+22 truncation, in which ETS sites 1-3 become deleted, and the -145/+22 truncation, in which additionally ETS sites 4 and 5 become removed, were at least as active as the longest YAP1 promoter (-390/+22) fragment in the absence or presence of ectopic ERG in the VCaP prostate cancer cells (Fig. 3A), suggesting that ETS sites 1-5 are not important for ERG-dependent YAP1 promoter upregulation. When ETS sites 1-7 were removed in the -62/+22 promoter construct, promoter activity was vastly reduced, suggesting that ETS sites 6 and 7 are crucial for YAP1 promoter activity. This would be consistent with the fact that ETS sites 6 and 7 were most avidly bound by ERG as shown above.

To corroborate this, we mutated ETS sites in the -390/+22 YAP1 promoter construct. Neither mutation of ETS site 1 or 2 resulted in decreased promoter activity, and even joint mutation of these two ETS sites had, in contrast to VCaP cells (compare to Fig. 3B), also a small effect (Fig. 4A). This suggests that in some
cell lines, ETS sites 1 and 2 may contribute to ERG-dependent YAP1 upregulation. Utilizing chromatin immunoprecipitation assays, we observed that expression of ERG led to no significant changes of trimethylation on histone H3 lysines K4, K27 and K36, but K9me3 levels were reduced on the YAP1 luciferase reporter (Fig. 4B). H3K9me3 is normally a marker for transcriptional repression (43), thus, it would be consistent that its removal contributes to ERG-mediated transcriptional activation.

This result led us to speculate that ERG may recruit a histone demethylase targeting trimethylated H3K9. Only one subclass of histone demethylases, the KDM4 proteins, is known for demethylating H3K9me3 (44). Hence, we focused on the protagonist of this family, KDM4A (45), and tested whether it would interact with ERG. To this end, we coexpressed Myc-tagged ERG and HA-tagged KDM4A in 293T cells and observed that KDM4A coprecipitated with ERG (Fig. 5A). Moreover, we produced a GST-ERG fusion protein in bacteria and challenged it with KDM4A purified from baculovirus. Whereas GST-ERG bound KDM4A, GST did not (Fig. 5B), indicating that ERG and KDM4A can directly bind to each other.

We then determined whether KDM4A would cooperate with ERG in activating YAP1 gene transcription. On its own, KDM4A had a modest impact on YAP1 luciferase activity in VCaP cells, but combined with ERG it caused a synergistic activation of the YAP1 promoter (Fig. 6). We also employed a catalytically inactive KDM4A protein, the H188A point mutant (46,47). This mutant was less active compared to wild-type KDM4A, yet still significantly raised ERG-mediated YAP1 luciferase activity (Fig. 6). These data suggest that KDM4A is a coactivator that stimulates ERG in a manner dependent and independent of its catalytic activity.

Relationship between ERG/KDM4A and YAP1 in VCaP cells. Next, we wished to confirm that YAP1 is a target gene of ERG and KDM4A in VCaP prostate cancer cells. To this end, we downregulated either ERG or KDM4A with two different shRNAs and observed that YAP1 protein levels were reduced (Fig. 7A and B, top panels). This suggested that both ERG and KDM4A are required for maximal YAP1 gene transcription in VCaP cells. Furthermore, we assayed VCaP cell growth upon ERG and KDM4A downregulation. As previously reported (48,49), ERG knockdown led to a robust decrease in VCaP cell growth (Fig. 7A, bottom panel). Notably, the same was observed upon KDM4A knockdown (Fig. 7B, bottom panel), highlighting a role of KDM4A in cell proliferation. We then
reasoned that whether YAP1 is a seminal downstream target of both ERG and KDM4A, its downregulation should phenocopy the observed reduction in cell growth upon ERG/KDM4A knockdown. In addition, indeed, we observed that YAP1 was required for maximal VCaP cell proliferation (Fig. 7C).

Discussion

In the present study, we uncovered a new mechanism by which ERG may exert its oncogenic function. This mechanism involves a physical interaction of ERG with the histone demethylase KDM4A that could lead to pleiotropic changes in the transcriptome, including an upregulation of YAP1 gene transcription. Since ERG overexpression is found in approximately half of all prostate tumor patients (4), our findings particularly pertain to prostatic malignancies.

YAP1 is a transcriptional cofactor that can be recruited to chromatin by several DNA-binding proteins. Frequently, YAP1 expression is enhanced in various human tumors and may correlate with poor prognosis, and its oncogenic potential was confirmed both in vitro as well as in transgenic mouse models (12,13). However, recent studies suggest that YAP1 may also exert growth suppressive actions in the colon and hematological cancers (50,51), suggesting that YAP1 context-dependently acts as an oncogene or tumor suppressor. However, the fact that YAP1 is overexpressed in human prostate tumors (52) indicates that it functions as an oncogene in this organ, which is consistent with prostate-specific overexpression of YAP1 leading to the development of prostatic neoplasias in mice (7). All this stresses that YAP1 may serve as a target for therapy particularly in ERG-overexpressing prostate tumors. Notably, small molecules as well as a peptide that suppress YAP1 function have been identified (53,54), which could be harnessed for future avenues of therapeutic interference. A caveat is that our report does not establish whether YAP1 is the only crucial downstream effector of ERG. Given that ERG downregulation seems to be more detrimental to VCaP cell proliferation than YAP1 downregulation (see Fig. 7), it is likely that YAP1 upregulation is not the sole reason why ERG overexpression induces prostate tumors. Yet, even partially blunting ERG’s oncogenic potential through YAP1 inhibition would still have therapeutic value.

KDM4A is the protagonist of the KDM4 family of histone demethylases that are encoded by six different genes in the human genome (45,55). It is particularly competent in demethylating trimethylated lysine 9 on histone H3 and lysine 26 on histone H1.4 that are regarded as repressive chromatin marks (46,47,56,57). Accordingly, KDM4A may function as

Figure 7. Impact of ERG, KDM4A and YAP1 on VCaP prostate cancer cells. (A) Cell growth (averages with standard deviations) upon downregulation of ERG with two different shRNAs. The top panels show western blot analyses of ERG, actin or YAP1. (B and C) Analogous for downregulation of KDM4A or YAP1. *p<0.05; **p<0.01; ***p<0.005; ****p<0.001.
a transcriptional coactivator at least in part by removing these repressive marks. However, we observed that catalytically inactive KDM4A was still capable, albeit at a much reduced rate compared to wild-type KDM4A, to cooperate with ERG in stimulating the YAP1 promoter. This suggests that KDM4A coactivates ERG both in a manner dependent on and independent of its catalytic activity. Likewise, Drosophila KDM4A has been shown to often affect gene transcription independent of its catalytic activity (58) and also mammalian KDM4A can impact DNA repair without involving its catalytic activity (59), corroborating that KDM4A may act both as an enzyme and in non-enzymatic ways.

However, in case of stimulating ERG, our data suggest that KDM4A is mostly acting through its enzymatic activity. If so, inhibition of its catalytic center may prove beneficial in the treatment of prostate cancer patients that are afflicted by an ERG chromosomal translocation. Several small molecules have been uncovered that can inhibit KDM4A enzymatic activity (60-66). However, the specificity of these inhibitors, their selectivity for suppressing tumor vs. normal cells, their toxicity, pharmacokinetics and pharmacodynamics need to be further explored before any of these inhibitors can enter clinical trials.

Similar to ERG, KDM4A seems to be overexpressed in prostate tumors (67), which would be alike to breast and lung tumors that display overexpression of KDM4A (68-71). This may suggest that KDM4A is oncogenic in its own right in the prostate, breast or lung. Furthermore, it is unlikely that KDM4A exclusively promotes prostate tumorigenesis as a coactivator of ERG. For instance, KDM4A can also stimulate the androgen receptor or repress the p53 tumor suppressor thereby leading to abnormal cell growth (72,73). Moreover, KDM4A is capable of inducing copy number gains in cells, which may represent another mechanism by which it contributes to the development of cancer (74).

In conclusion, the present study has provided more mechanistic insight into how ERG overexpression due to chromosomal translocations can induce prostate cancer formation. Despite its obvious validity as a drug target in prostate cancer, no effective ERG inhibitors have surfaced in the clinic, which may be due to the difficulty of targeting a DNA-binding transcription factor. The present study suggests two alternative targets to blunt the ERG oncogenic activity, KDM4A and YAP1, both of which can in principal be inhibited by small molecules and may therefore merit more research.

Acknowledgements

The present study was in part funded by a grant from the National Institutes of Health/National Cancer Institute (R01 CA154745) to R.J. The content is solely the responsibility of the authors and does not necessarily represent the official views of the granting agencies.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Ryan CJ and Tindall DJ: Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29: 3651-3658, 2011.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al: Recurrent mutation of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648, 2005.
4. Clark JP and Cooper CS: ETS gene fusions in prostate cancer. Nat Rev Urol 6: 429-439, 2009.
5. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS and Vaisoukhan V: A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 105: 2105-2110, 2008.
6. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson SE, Cao Q, Prensner JR, Rubin MA, Shah RB, et al: Role of the TMPRSS2-ETS gene fusion in prostate cancer. Neoplasia 10: 177-188, 2008.
7. Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, Bolouri H, Kutyavin VI, Morrisey C, True LD, et al: ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors. Cancer Cell 27: 797-808, 2015.
8. Tak1-BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, et al: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41: 619-624, 2009.
9. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, et al: Cooperativity of TMPRSS2-ETS with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526, 2009.
10. Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, et al: ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 27: 683-698, 2013.
11. Chen Y, Chi P, Romwitz S, Jaquinta PJ, Shamu T, Shukla S, Gao D, Sirotta I, Carver BS, Wongvipat J, et al: ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 19: 1023-1029, 2013.
12. HarveyKF, Zhang X and Thomas DM: The Hippo pathway and human cancer. Nat Rev Cancer 13: 246-257, 2013.
13. Varelas X: The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141: 1614-1626, 2014.
14. Dowdy SC, Mariani A and Janknecht R: HER2/Neu- and PI3K-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem 278: 44377-44384, 2003.
15. Mooney SM, Grande JP, Salisbury JL and Janknecht R: Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry 49: 1-10, 2010.
16. Oh S, Shin S, Lightfoot SA and Janknecht R: 14-3-3 proteins modulate the ETS transcription factor ETV1 in prostate cancer. Cancer Res 73: 5110-5119, 2013.
17. Wang and Janknecht R: Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J Biol Chem 277: 42669-42679, 2002.
18. Papoutsopoulou S and Janknecht R: Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol 20: 7300-7310, 2000.
19. De Haro L and Janknecht R: Cloning of the murine ER71 gene (Etsrp71) and initial characterization of its promoter. Genomics 85: 493-502, 2005.
20. DiTacchio L, Bowles J, Shin S, de Haro L, Koopman P and Janknecht R: Transcription factors ER71/ETV2 and SOX9 participate in a positive feedback loop in fetal and adult mouse testis. J Biol Chem 287: 23657-23666, 2012.
21. De Haro L and Janknecht R: Functional analysis of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J Biol Chem 277: 44377-44384, 2002.
22. De Haro L and Janknecht R: Pleiotropic effects of p300-mediated acetylation on the ETS protein ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J Biol Chem 277: 42669-42679, 2002.
25. Goel A and Janknecht R: Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol 23: 6243-6254, 2003.

26. Goel A and Janknecht R: Concerted activation of ETS protein ER81 by p300, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 279: 14909-14916, 2004.

27. Berry WL, Kim TD and Janknecht R: Stimulation of β-catenin and colon cancer cell growth by the KDM4B histone demethylase. Int J Oncol 44: 1341-1348, 2014.

28. Janknecht R: Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 22: 746-755, 2003.

29. Shin S, Bosc DG, Ingle JN, Spelsberg TC and Janknecht R: Rcl demethylase family. Biochem Biophys Res Commun 353: 8042-8047, 2003.

30. Goueli BS and Janknecht R: Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Oncogene 22: 8042-8047, 2003.

31. Shin S, Rossow KL, Grande JP and Janknecht R: Involvement of RNA helicases p68 and p72 in colon cancer cells. Cancer Res 67: 7572-7578, 2007.

32. Shin S, Oh S, An S and Janknecht R: ETS variant 1 regulates matrix metalloproteinase-7 transcription in LNCaP prostate cancer cells. Oncol Rep 29: 306-314, 2013.

33. Goueli BS and Janknecht R: Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol 24: 25-35, 2004.

34. Shin S, Kuo TD, Jin F, van Deursen JM, Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatsitis G and Janknecht R: Induction of prostate intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res 69: 8102-8110, 2009.

35. Kim TD, Oh S, Shin S and Janknecht R: Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PLoS One 7: e34618, 2012.

36. Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F, Geng J, Tian J, Sun X, Qin F, et al: The ETS transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. Cell Reports 3: 1663-1677, 2013.

37. Haffner MC, Aryee MJ, Touba A, Esopi DM, Albardine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, et al: Structural and dynamic studies of the ETS transcription factor ER81 by p300, P/CAF, and the Jumonji domain-containing JMJD2/KDM4 proteins. J Biol Chem 284: 8395-8405, 2009.

38. Hollandhorst PC, McIntosh LP and Graves BJ: Genomic and biochemical insights into the specificity of ETS transcription factors. Angewandte Chemie Int Ed 48: 437-471, 2009.

39. Regan MC, Horanyi PS, Fyoor EY Jr, Arber SA, Cifoso DS and Bushweller JH: Structural and dynamic studies of the transcription factor ERG reveal DNA binding is allosterically autoinhibited. Proc Natl Acad Sci USA 110: 13374-13379, 2013.

40. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, Enge M, Pouyssegur J, Kallioniemi O, Sauter G, et al: Combined nondenaturing mass spectrometric screening and crystallographic approaches. J Med Chem 53: 1810-1818, 2010.

41. Mallette FA, Mattiroli F, Cui G, Young LC, Hendzel MJ, Mer G, Podoll J, Heightman TD, Oppermann U, Podobnik M, Jolma A, Varjosalo M, Gehrke AR, et al: Selective inhibitors of the cellular functions of Jumonji C-domain-containing histone demethylases. Nat Chem Biol 6: 1-15, 2013.

42. Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P, Wong J and Zhang Y: The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 442: 312-316, 2006.

43. Tijer P, Zhang J, Yonezawa M, Schmid A, Zheng H, Jennewein T and Reinberg D: Dynamic histone H1 isoform 4 methylation and demethylation by histone lysine methyltransferase G9a/KMT1C and the Junmomi domain-containing JMD2/KDM4 proteins. J Biol Chem 284: 8395-8405, 2009.

44. Davis F, Dahlgren G, Lundberg LE, Larsson J and Mannervik B: Gene regulation by the lysine demethylase KDM4A in Drosophila. Dev Biol 373: 453-463, 2013.

45. Mallette FA, Mattiroli F, Cui G, Young LC, Hendzel MJ, Mer G, Sixma TK and Richard S: RNAF8- and RNAF16-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J 31: 1865-1872, 2012.

46. Hamada S, Kim TD, Suzuki T, Itoh Y, Takimoto H, Nakagawa H, Janknecht R and Miyata N: Synthesis and activity of N-oxalylglycine and its derivatives as Junmomi C-domain-containing histone lysine demethylase inhibitors. Bioorg Med Chem Lett 19: 2852-2855, 2009.

47. Hamada S, Suzuki T, Mino K, Koseki K, Oehme F, Flamme I, Ozasa I, Itoh Y, Ogawara D, Komaarashi H, et al: Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of junmomi domain-containing protein 2 histone demethylase inhibitors. J Med Chem 53: 5629-5638, 2010.

48. Rose NR, Woon EC, Kingham GL, King ON, Mecinovic J, Clifton JJ, Ng SS, Talib-Hardy JD, Oppermann U, McDonagh MA, et al: Selective inhibitors of the JMJD2 histone demethylases: Combined nonnudaturing mass spectrometric screening and crystallographic approaches. J Med Chem 53: 1810-1818, 2010.

49. King ON, Li XS, Sakurai M, Kawamura A, Rose NR, Ng SS, Zhang Z, Wang W, et al: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25: 166-180, 2014.

50. Labbé RM, Holowayt A and Yang ZQ: Histone lysine demethylation (KDM) subfamily 4: Clinical applications and therapeutic potential. Am J Transl Res 6: 1-15, 2013.

51. Kim TD, Oh S, Shin S and Janknecht R: Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D. PLoS One 7: e34618, 2012.
66. Kim TD, Fuchs JR, Schwartz E, Abdelhamid D, Etter J, Berry WL, Li C, Ihnat MA, Li PK and Janknecht R: Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoinds as JMJD2 inhibitors. Am J Transl Res 6: 236-247, 2014.

67. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH and Helin K: The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442: 307-311, 2006.

68. Patani N, Jiang WG, Newbold RF and Mokbel K: Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res 31: 4115-4125, 2011.

69. Berry WL, Shin S, Lightfoot SA and Janknecht R: Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol 41: 1701-1706, 2012.

70. Slee RB, Steiner CM, Herbert BS, Vance GH, Hickey RJ, Schwarz T, Christian S, Radovich M, Schneider BP, Schindelhauer D, et al: Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability. Oncogene 31: 3244-3253, 2012.

71. Mallette FA and Richard S: JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5. Cell Reports 2: 1233-1243, 2012.

72. Shin S and Janknecht R: Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun 359: 742-746, 2007.

73. Kim TD, Shin S, Berry WL, Oh S and Janknecht R: The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem 113: 1368-1376, 2012.

74. Black JC, Manning AL, Van Rechem C, Kim J, Ladd B, Cho J, Pineda CM, Murphy N, Daniels DL, Montagna C, et al: KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell 154: 541-555, 2013.